Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;100(1):23-40.
doi: 10.1177/00914150241268259. Epub 2024 Aug 16.

Overcoming Barriers to Latino Participation in Alzheimer's Disease Research

Affiliations

Overcoming Barriers to Latino Participation in Alzheimer's Disease Research

Kevyn A Ramirez et al. Int J Aging Hum Dev. 2025 Jan.

Abstract

There is a critical need to increase Latino participation in research on Alzheimer's disease and related disorders (ADRD). Applying principles of community-based participatory research, we convened a community advisory board (CAB) to identify barriers and recommend strategies to increase participation of older Latinos in a longitudinal observational research study of ADRD at the Shiley-Marcos Alzheimer's Disease Research Center. Six major barriers were identified and programmatic changes to overcome them were implemented. Changes resulted in a nearly three-fold increase in the number of Latino individuals recruited, with the proportion of all newly recruited participants who were Latino increasing from 12.2% to 57.4%. Newer Latino recruits were more representative of the elderly Latino population in San Diego County than those recruited pre-CAB and remained highly agreeable to blood draw and neuroimaging, though less so to lumbar puncture and autopsy. Results demonstrate the value of CAB involvement in enhancing diversity in ADRD research.

Keywords: Alzheimer's disease; Latino; advancing diversity in aging research; recruitment; research barriers.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: David P. Salmon is a paid consultant for Biogen and Aptinyx. Douglas Galasko is a paid consultant for Eisai, Biogen, Roche Diagnostics, GE Healthcare, and Fujirebio, Inc., and is on the Data and Safety Monitoring Board (DSMB) for Artery Therapeutics. James B. Brewer reports equity interest in Cortechs.ai, Enkephalos, Impact Biomedicines, ACLIP, and Human Longevity, Inc. All other authors have declared no conflicts of interest.

LinkOut - more resources